Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and...
EHR
Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology...
Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFM
BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet SystemHACKENSACK, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Royal Biologics, a company...
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused...
NRC Health recognized as Best in KLAS for Patient Experience Improvement
Top-ranking reinforces commitment to service and humanized care as industry standard Best in KLAS 2023 Best in KLAS Patient Experience...
Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference
LEXINGTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb....
VitalHub Announces a Multi-Year Licensing of the TREAT Client Information System to Habitat Services
TORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue...
Inovalon Adds All-payer Claims Management Software to the PointClickCare Marketplace, Expanding Partnership
Latest EHR Integration from Inovalon Offers Healthcare Providers 99% First Pass Claims Acceptance RateBOWIE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE)...
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Expects to Commence Phase 2a of CAReS During the First Quarter of 2023SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE)...
OrthoPediatrics Corp. Publishes Environmental, Social, and Governance (“ESG”) Summary Report
WARSAW, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively...
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development...
SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
DENVER, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce...
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast...
Lumanity Expands Medical Affairs Capabilities
LUMANITY EXPANDS MEDICAL AFFAIRS CAPABILITIES Enhanced solutions to deliver effective medical strategies, cross-functional communication plans, and programs to connect with...
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA,...
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in...
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint...